» Articles » PMID: 32055822

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity

Abstract

Background: Dopamine D1 receptor signaling plays key roles in core domains of neural function, including cognition and reward processing; however, many questions remain about the functions of circuits modulated by dopamine D1 receptor, largely because clinically viable, selective agonists have yet to be tested in humans.

Methods: Using a novel, exploratory neurofunctional domains study design, we assessed the safety, tolerability, pharmacodynamics, and pharmacokinetics of PF-06412562, a selective D1/D5R partial agonist, in healthy male volunteers who met prespecified criteria for low working memory capacity. Functional magnetic resonance imaging, electrophysiologic endpoints, and behavioral paradigms were used to assess working memory, executive function, and motivation/reward processing following multiple-dose administration of PF-06412562. A total of 77 patients were assigned PF-06412562 (3 mg twice daily and 15 mg twice daily) or placebo administered for 5 to 7 days. Due to the exploratory nature of the study, it was neither powered for any specific treatment effect nor corrected for multiple comparisons.

Results: Nominally significant improvements from baseline in cognitive endpoints were observed in all 3 groups; however, improvements in PF-06412562-treated patients were less than in placebo-treated participants. Motivation/reward processing endpoints were variable. PF-06412562 was safe and well tolerated, with no serious adverse events, severe adverse events, or adverse events leading to dose reduction or temporary discontinuation except for 1 permanent discontinuation due to increased orthostatic heart rate.

Conclusions: PF-06412562, in the dose range and patient population explored in this study, did not improve cognitive function or motivation/reward processing more than placebo over the 5- to 7-day treatment period.

Clinicaltrials.gov Identifier: NCT02306876.

Citing Articles

A Kpna1-deficient psychotropic drug-induced schizophrenia model mouse for studying gene-environment interactions.

Nomiya H, Sakurai K, Miyamoto Y, Oka M, Yoneda Y, Hikida T Sci Rep. 2024; 14(1):3376.

PMID: 38336912 PMC: 10858057. DOI: 10.1038/s41598-024-53237-3.


Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.

Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S CNS Neurol Disord Drug Targets. 2023; 23(4):476-487.

PMID: 36999711 PMC: 10909821. DOI: 10.2174/1871527322666230331121028.


Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate.

Castner S, Zhang L, Yang C, Hao J, Cramer J, Wang X Psychopharmacology (Berl). 2023; 240(5):1033-1048.

PMID: 36961560 PMC: 10102062. DOI: 10.1007/s00213-022-06282-7.


Experimental Medicine Approaches in Early-Phase CNS Drug Development.

English B, Ereshefsky L Adv Neurobiol. 2023; 30:417-455.

PMID: 36928860 DOI: 10.1007/978-3-031-21054-9_17.


Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Miskowiak K, Yalin N, Seeberg I, Burdick K, Balanza-Martinez V, Bonnin C Bipolar Disord. 2022; 24(6):615-636.

PMID: 35950925 PMC: 9826389. DOI: 10.1111/bdi.13247.


References
1.
Collins A, Frank M . Opponent actor learning (OpAL): modeling interactive effects of striatal dopamine on reinforcement learning and choice incentive. Psychol Rev. 2014; 121(3):337-66. DOI: 10.1037/a0037015. View

2.
OReilly R . Biologically based computational models of high-level cognition. Science. 2006; 314(5796):91-4. DOI: 10.1126/science.1127242. View

3.
WATSON D, Clark L, Tellegen A . Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988; 54(6):1063-70. DOI: 10.1037//0022-3514.54.6.1063. View

4.
McCambridge J, Witton J, Elbourne D . Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2013; 67(3):267-77. PMC: 3969247. DOI: 10.1016/j.jclinepi.2013.08.015. View

5.
Okubo Y, Suhara T, Sudo Y, Toru M . Possible role of dopamine D1 receptors in schizophrenia. Mol Psychiatry. 1997; 2(4):291-2. DOI: 10.1038/sj.mp.4000281. View